Amiodarone
- PDF / 169,927 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 81 Downloads / 133 Views
1
S
Thyrotoxicosis: case report A 55-year-old man developed thyrotoxicosis during treatment with amiodarone for atrial fibrillation. The man, who had systolic heart failure and atrial fibrillation, and had been receiving amiodarone [dosage and route not stated], presented with tachycardia, anxiety, excessive sweating and diarrhoea. Laboratory tests revealed TSH 0.03, positive thyroglobulin level and thyroid peroxidase antibodies, free T4 10 and negative thyroid stimulating immunoglobulin antibodies. The man’s treatment with amiodarone was discontinued and he started receiving alternative unspecified antiarrhythmic drugs. He started receiving treatment with thiamazole [methimazole], saturated solution of potassium iodide, hydrocortisone, colestyramine [cholestyramine] and lithium without any improvement in free T4 levels. Thereafter, he had 3 cycles of plasmapheresis with improvement in free T4 levels. Then, he underwent total thyroidectomy. Surgical pathology revealed foamy macrophages, thyroid follicles with reduced colloid, desquamated epithelial cells and lymphocytes consistent with the diagnosis of amiodarone induced thyrotoxicosis [duration of treatment to reaction onset not stated]. After surgery, he started receiving levothyroxine sodium [levothyroxine] and was discharged from the hospital. Author comment: "Surgical Pathology - Thyroid follicles with reduced colloid, foamy macrophages, desquamated epithelial cells/ lymphocytes [consistent with] amiodarone induced hyperthyroidism." Chohan AA, et al. Medical therapy resistance in amiodarone induced thyrotoxicosis leading to plasmapheresis and total thyroidectomy. Thyroid 29 (Suppl. 1): A110-A111 abstr. Poster 313, Oct 2019. Available from: URL: http:// 803436785 doi.org/10.1089/thy.2019.29085.abstracts [abstract] - USA
0114-9954/19/1781-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 30 Nov 2019 No. 1781
Data Loading...
